Introduction
============

Parkinson's disease (PD) is the second most common neurodegenerative disease characterized by progressive loss of dopaminergic neurons in substantia nigra. While hereditary PD is mainly caused by gene mutations such as in *SNCA, Parkin*, and *PINK1*, the majority of this disease is sporadic and the pathogenesis involves both genetic vulnerabilities and environmental exposures ([@B3]). Thus far, diagnosis of PD largely relies on the presence of motor symptoms, clinically characterized by bradykinesia, resting tremor, rigidity, and at late stage gait instability. However, the actual onset of this disease precedes the motor manifestations by a number of years ([@B27]). As a consequence, possible clinic or preventive interventions lag far behind the disease onset. Substantial efforts have therefore been made to develop potential markers for early diagnosis of PD, and the strategies include prodromal clinical signs, imaging, skin or colonic biopsies, genetic sequencing, and biochemical testing in cerebral spinal fluid, blood, saliva, and urine. For example, certain non-motor symptoms such as olfactory impairment and rapid eye movement sleep behavior disorder, which are frequently present in PD before motor manifestations, have been under investigation as potential markers for PD diagnosis ([@B44]). Unfortunately, thus far none of them has been proven effective in clinical trials despite early promises ([@B27]).

MicroRNAs (miRNAs) act as endogenous regulators of gene expression by binding to complementary sequences of target messenger RNA ([@B9]). Being small non-protein coding RNAs and also relatively stable, disturbance of miRNA in tissues is possibly reflected by changes in serum/plasma, which renders miRNA a potentially convenient biomarker in monitoring diseases ([@B47]). miRNAs have also been suggested to play an important role in PD and profiled in brains of PD patients ([@B30]; [@B40]). Among the miRNAs known to be associated with PD, in particular those with postmortem evidence and/or regulating α-synuclein expression, are: miR-34b and miR-34c, down-regulated in the brains of PD patients ([@B40]; [@B56]) and repressing α-synuclein expression ([@B26]); miR-7 and miR-153, suppressing α-synuclein expression ([@B25]; [@B14]); miR-433, regulating fibroblast growth factor 20 (FGF20) levels and subsequent α-synuclein expression ([@B57]); and miR-133b, down-regulated in midbrain of PD patients and interacting with Pitx3 ([@B30]). In this study, we focused on these six miRNAs to better understand PD-associated changes and explore their potentiality as PD biomarkers.

Materials and Methods {#s1}
=====================

Study Subjects
--------------

A total of 95 Han Chinese individuals were enrolled in this study, consisting of 46 sporadic PD patients (22 men and 24 women) and 49 controls (22 men and 27 women). The age of the patients and controls was 63.13 ± 1.46 and 60.35 ± 1.16, respectively. The two groups were comparable by gender (*P* = 0.78) and age (*P* = 0.14). The patients were diagnosed by two movement disorder neurologists according to the UK Parkinson's Disease Society Brain Bank Criteria, and were not with a family history of PD or secondary and atypical parkinsonism. The control subjects were free of neurological disorders by medical history, physical and laboratory examinations. The PD patients were divided into three subgroups according to Hoehn and Yahr (H&Y) staging ([@B20]) including stage I (H&Y stage: 1--2), stage II (H&Y stage: 3--4), and stage III (H&Y stage: 5). All subjects participating in this study signed informed written consents. The study was approved by the ethics committee of the Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University.

Plasma Sample Collection and miRNA Extraction
---------------------------------------------

Fasting blood samples were collected in EDTA tubes and centrifuged for 15 min at 1500 rpm at room temperature. After centrifugation, plasma was collected and stored at -80°C until analysis. RNAs enriched of small size were extracted from 500 μl of aliquots using miRcute miRNA isolation Kit (Tiangen, Beijing, China) according to the manufacturer's instruction.

Determination of miRNA Levels by RT-qPCR
----------------------------------------

Sequences and miRBase accession numbers of the assessed miRNAs were listed in **Table [1](#T1){ref-type="table"}**. RNA (50 ng) was reverse-transcribed using FastQuant RT Kit with gDNase (Tiangen, Beijing, China). qPCR was performed using FastStart Essential DNA Green Master (Roche, Mannheim, Germany) in accordance with the manufacturer's instruction in CFX Connect^TM^ Real-Time PCR detection system (Bio-Rad Laboratories, Hercules, CA, United States). Small nucleolar RNA U6 was used as an internal control. The RT and PCR primers for each miRNA and U6 were purchased from RiboBio (Guangzhou, China), termed Bulge-Loop^TM^ miRNA RT-qPCR (reverse-transcription quantitative PCR) primer set and U6 stem-loop RT-qPCR primer set, respectively. Each reaction was performed with triplicates with cycling conditions as follows: 95°C for 10 min, followed by 45 cycles of 95°C for 10 s, 60°C for 15 s, and 72°C for 20 s. The miRNA expression levels were calculated as 2^-Δct^, wherein the average cycle threshold ([@B39]) value of each miRNA was subtracted by their respective Ct value of U6.

###### 

The miRNA sequences and miRBase accession numbers.

  Assayed miRNA    Sequence                  Accession number
  ---------------- ------------------------- ------------------
  hsa-miR-433-3p   AUCAUGAUGGGCUCCUCGGUGU    MIMAT0001627
  hsa-miR-133b     UUUGGUCCCCUUCAACCAGCUA    MIMAT0000770
  hsa-miR-34b-3p   CAAUCACUAACUCCACUGCCAU    MIMAT0004676
  hsa-miR-34c-5p   AGGCAGUGUAGUUAGCUGAUUGC   MIMAT0000686
  hsa-miR-7-5p     UGGAAGACUAGUGAUUUUGUUGU   MIMAT0000252
  hsa-miR-153-3p   UUGCAUAGUCACAAAAGUGAUC    MIMAT0000439

Pathway and Gene Ontology Analyses of miRNA Targets
---------------------------------------------------

The miRNA target genes were sequentially analyzed using miRTarBase^[1](#fn01){ref-type="fn"}^ (release 4.5; a database that has experimentally validated the miRNA-target interactions; [@B23]), and in DAVID^[2](#fn02){ref-type="fn"}^ (Database for Annotation, Visualization and Integrated Discovery; [@B24]), a web-accessible program that integrates functional genomic annotations with intuitive graphical summaries, to identify KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways ([@B28]), followed by gene ontology (GO) analyses ([@B2]; [@B16]).

Supervised Learning Algorithms
------------------------------

Six algorithm models were generated using R (version 3.1.2), including decision tree ([@B46]), conditional inference tree ([@B22]), random forest ([@B49]), support vector machine ([@B11]), naive Bayesian ([@B33]), and logistic regression ([@B21]). Model performance was assessed using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity and specificity. The model metrics were obtained from internal fivefold cross-validation with 100 repeats.

Statistical Analysis
--------------------

Statistical analysis was performed using Statistical Product and Service Solutions (SPSS; version 20.0) for windows. Differences in gender and age between patients and controls were assessed using χ^2^ test and *t*-test, respectively. Differences in miRNA expression levels between patients and controls were evaluated using Mann--Whitney *U*-test following normality analysis using Kolmogorov--Smirnov test and Shapiro--Wilk test with or without logarithm and square root transformations. Outliers, which differed more than 30 times from the median, were excluded by using informal box plots to pinpoint the outlying points ([@B32]). Spearman's rank correlation coefficient was calculated to estimate the association between levels of each miRNA. Fisher *Z* transformation was used to analyze differences in correlation coefficients of the miRNA pairs between the patient and control groups, and a *z* value outside of the range of -1.96∼1.96 was considered as *P* \< 0.05. Values were expressed as means ± SE unless otherwise indicated. A difference was considered statistically significant when a two-tailed *P*-value was \<0.05.

Results
=======

Expression of the Six miRNAs in Plasma of PD Patients and Controls
------------------------------------------------------------------

We first randomly selected three control and three PD samples to determine whether the six miRNAs could be reliably detected in plasma under our condition as described in Section "Materials and Methods." An average qPCR Ct value of 40 was considered as a detection limit in this study as values beyond indicate minute abundance ([@B15]; [@B42]). The results showed that levels of miR-34c (Ct, 41.5 ± 0.41) and miR-7 (beyond detection limit) were very low in plasma. In contrast, the other four miRNAs, including miR-433 (Ct, 38.1 ± 1.57), miR-133b (Ct, 33.2 ± 0.29), miR-34b (Ct, 37.5 ± 0.94), and miR-153 (Ct, 38.9 ± 0.65), were constantly detectable. We thus measured and analyzed expression levels of these four miRNAs in the following experiments. The expression levels of miR-433 (**Figure [1A](#F1){ref-type="fig"}**; *P* = 0.003) and miR-133b (**Figure [1B](#F1){ref-type="fig"}**; *P* = 0.006) were significantly lower in plasma of PD patients compared with the controls. In contrast, no significant difference was found in miR-34b (**Figure [1C](#F1){ref-type="fig"}**) and miR-153 (**Figure [1D](#F1){ref-type="fig"}**) between the controls and PD cases. Of note, four samples (one in controls; three in PD) were excluded in the group of miR-133b based on the outlier calculation. Some studies did not use any controls but kept the reaction system consistent throughout experiments, and straightforwardly used the measured levels ([@B10]; [@B48]). The current study followed a consistent system as well; we thus applied this method by removing the normalization of U6, and detected similar results (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}).

![Levels of miR-433 **(A)**, miR-133b **(B)**, miR-34b **(C)**, and miR-153 **(D)** in plasma of Parkinson's disease (PD) patients and controls. Expression of miRNAs was expressed relative to their respective level of U6. The bar represents median with interquartile range.](fncel-11-00170-g001){#F1}

Analysis of Correlation between the Four miRNAs in PD Patients and Controls
---------------------------------------------------------------------------

Correlations were analyzed to understand potential links within miR-433, miR-133b, miR-34b, and miR-153. The strongest correlation was present between miR-433 and miR-133b (*r*~s~ = 0.87 and 0.85, respectively, in the control and PD groups; **Figure [2A](#F2){ref-type="fig"}**), followed by the correlation between miR-133b and miR-34b in the controls (*r*~s~ = 0.78; **Figure [2D](#F2){ref-type="fig"}**). The results showed a pattern of reduction in miRNA correlations from the controls to patients (**Figure [2](#F2){ref-type="fig"}**). However, only the coefficient of the pair of miR-34b and miR-153 was significantly reduced in PD cases compared with that in the controls (*z* = 2.31; **Figure [2F](#F2){ref-type="fig"}**). In contrast, the other reductions from the controls to patients were not significant (**Figures [2A](#F2){ref-type="fig"}--[E](#F2){ref-type="fig"}**; *z* = 0.35 for the pair of miR-433 and miR-133b; *z* = 1.55 for miR-433 and miR-34b; *z* = 1.89 for miR-433 and miR-153; *z* = 1.32 for miR-133b and miR-34b; *z* = 1.22 for miR-133b and miR-153). No correlation was found between age and miRNA expression levels in both control and PD groups (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). We also analyzed whether levels of the miRNAs were associated with disease severity, but found no difference among the three stages of our PD patients (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}).

![Correlation analyses between miR-433 and miR-133b **(A)**, miR-433 and miR-34b **(B)**, miR-433 and miR-153 **(C)**, miR-133b and miR-34b **(D)**, miR-133b and miR-153 **(E)**, as well as miR-34b and miR-153 **(F)** in Parkinson's disease (PD) and control (Ctrl) groups. Spearman's rank correlation coefficient (*r*~s~) along with 95% confidence intervals (CI) and *P*-values are listed above each chart.](fncel-11-00170-g002){#F2}

Pathway Analysis, GO Analysis, and PD Prediction Modeling
---------------------------------------------------------

Given the PD-associated changes in miR-433 and miR-133b and their correlations, we performed further analyses to understand their potential target genes and similarities. Analysis in miRTarBase suggested 71 target genes for miR-433 and 67 for miR-133b (Supplementary Table [S3](#SM1){ref-type="supplementary-material"}). KEGG pathway analysis showed that the identified target genes of miR-433 were involved in 13 pathways and those of miR-133b were in 26 pathways, sharing seven pathways in common, including MAPK, PI3K-AKT, and Ras signaling pathways (**Figure [3A](#F3){ref-type="fig"}**). Results with statistical significance (*P* \< 0.05) from GO analysis showed no shared biological processes for miR-433 and miR-133b, while the later was involved in more processes (41 vs. 6). The most significant biological processes included phosphatidylinositol-mediated signaling, positive regulation of DNA replication, regulation of actin cytoskeleton organization, and fibroblast growth factor receptor signaling pathway (**Figure [3B](#F3){ref-type="fig"}**).

![Analyses of potential target genes for miR-433 and miR-133b. **(A)** KEGG pathway analysis of the target genes. The horizontal axis represents enrichment score. The number of enriched genes for each pathway is shown in parentheses in the vertical axis. The boxes indicate the common pathways shared by miR-433 and miR-133b. **(B)** Gene ontology analysis of the target genes. *P*-value was to examine the significance of gene-term enrichment with a modified Fisher's exact test. Only the pathways or biological processes with *P* \< 0.05 were shown.](fncel-11-00170-g003){#F3}

We also applied multiple supervised learning algorithms, including decision tree, conditional inference tree, random forest, support vector machine, naive Bayesian, and logistic regression, to model miR-433 and miR-133b for PD prediction (**Table [2](#T2){ref-type="table"}**). None of the models led to decent overall performance in terms of AUC, accuracy, sensitivity, and specificity based on the current data. Interestingly, a specificity of 0.87 was achieved by naive Bayesian classifier.

###### 

Algorithm models of miR-433 and miR-133b for PD prediction.

  Models                       AUC    Accuracy   Sensitivity   Specificity
  ---------------------------- ------ ---------- ------------- -------------
  Decision tree                0.59   0.58       0.56          0.61
  Conditional inference tree   0.56   0.54       0.42          0.68
  Random forest                0.59   0.59       0.59          0.59
  Support vector machine       0.58   0.56       0.52          0.62
  Naive Bayesian               0.62   0.61       0.37          0.87
  Logistic regression          0.59   0.58       0.55          0.63

AUC, the area under the receiver operating characteristic curve.

Discussion
==========

Deficiency in efficient biomarkers hinders timely intervention of PD and thus demands continuous endeavors. Aberrant miRNA expression has been suggested in a strength of linkage to sporadic PD ([@B18]). Herein, we demonstrate that plasma levels of miR-433 and miR-133b significantly differ between PD patients and controls, following screening a set of cell-free PD-associated miRNAs. These two miRNAs exhibit strong correlations in terms of their expression levels in plasma, and share several common signaling pathways.

miR-433 binds to the promoter region of *FGF20*. A variant, rs12720208, at the miRNA binding site of *FGF20* is associated with PD, as its risk allele prevents miR-433 from attaching and leads to increased FGF20 translation and subsequent α-synuclein expression ([@B57]). The reduced expression of miR-433 as suggested in plasma may contribute to increased FGF20 and α-synuclein expression, assuming that the plasma level reflects the changes in the brain. In accordance with our results, a recent profiling of extracellular miRNAs by small RNA sequencing also suggests a significant decrease of miR-433 in cerebrospinal fluid (CSF) of postmortem PD patients. Their profiling in serum shows five differentially expressed miRNAs (**Table [3](#T3){ref-type="table"}**), but no statistical difference was found in miR-433 and miR-133b ([@B6]). One possible reason for the discrepancy is that the profiling samples are from postmortem patients, which usually are at very late stage of the disease. Meanwhile, specific analysis by qPCR may be more sensitive than general sequencing profiling.

###### 

Aberrant expression of miRNAs in fluids or blood cells of PD patients.

  Studies               Sources      PD, *n*   Ctrl, *n*   Method            Increased miRNA                                                                                    Decreased miRNA
  --------------------- ------------ --------- ----------- ----------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B36]                Blood        8^1^      8           qPCR                                                                                                                 miR-1, miR-22^∗^, miR-29a
  [@B50]                Blood        36        36          qPCR              miR-29a, miR-30b, miR-103a                                                                         
  [@B53]                Leukocytes   7         6           NGS               miR-18b^∗^, miR-20a, miR-21, miR-150, miR-199b, miR-378c, miR-671, miR-1249, miR-1274b, miR-4293   miR-16, miR-92b, miR-320a, miR-320b, miR-320c, miR-769
  [@B38]                PBMCs        19        13          M-array                                                                                                              miR-19b, miR-26a, miR-28-5p, miR-29b, miR-29c, miR-30b, miR-30c, miR-126, miR-126^∗^, miR-147, miR-151-3p, miR-151-5p, miR-199a-5p, miR-199a/b-3p, miR-301a, miR-335, miR-374a, miR-374b
  [@B8]                 Plasma       31        25          qPCR/TLDA^2^      miR-331-5p                                                                                         
  [@B29]                Plasma       42        30          qPCR/M-array^2^   miR-222, miR-505, miR-626                                                                          
  [@B34]                Plasma       60        60          qPCR              miR-137                                                                                            miR-124
  Current study, 2017   Plasma       46        49          qPCR                                                                                                                 miR-133b, miR-433
  [@B6]                 Serum        50        62          NGS               miR-30a-3p, miR-30e-3p, miR-338-3p                                                                 miR-16-2-3p, miR-1294
  [@B4]                 Serum        65        65          TLDA                                                                                                                 miR-19b, miR-29a, miR-29c
  [@B7]                 Serum        109       40          qPCR              miR-24, miR-195                                                                                    miR-19b
  [@B12]                Serum        106       91          qPCR/S-seq^2^     miR-195                                                                                            miR-15b, miR-181a, miR-185, miR-221
  [@B13]                Serum        122       104         qPCR/S-seq^2^                                                                                                        miR-141, miR-146b-5p, miR-193a-3p, miR-214
  [@B35]                Serum        138       112         qPCR                                                                                                                 miR-29c, miR-146a, miR-214, miR-221
  [@B55]                Serum        25        25          qPCR/TLDA^2^      miR-24, miR-223^∗^, miR-324-3p                                                                     miR-30c, miR-148b
  [@B60]                Serum        46        46          qPCR                                                                                                                 miR-133b
  [@B6]                 CSF          57        65          NGS               miR-19a-3p, miR-19b-3p, let-7g-3p                                                                  miR-10a-5p, miR-127-3p, miR-128, miR-132-5p, miR-136-3p, miR-212-3p, miR-370, miR-409-3p, miR-431-3p, miR-433, miR-485-5p, miR-873-3p, miR-1224-5p, miR-4448
  [@B17]                CSF          78        35          qPCR/TLDA^2^      miR-10a-5p, miR-136-3p, miR-153, miR-409-3p, miR-433, let-7g-3p                                    miR-1, miR-19b-3p
  [@B37]                CSF          28        28          qPCR              miR-205                                                                                            miR-24

CSF, cerebrospinal fluid; Ctrl, controls; M-array, microarray; NGS, next generation sequencing; PBMCs, peripheral blood mononuclear cells; PD, Parkinson's disease; S-seq, Solexa sequencing; TLDA, TaqMan Low Density Array;

1

Untreated PD patients;

2

qPCR as validation after initial screening using array or sequencing.

The miR-133b is enriched in dopaminergic neurons and is deficient in midbrain tissues of PD patients ([@B30]). The miR-133b suppresses midbrain dopaminergic neuron maturation and function by targeting Pitx3 as disclosed in primary rat midbrain cultures ([@B30]). The deficiency of miR-133b in PD is further confirmed using laser microdissected postmortem dopaminergic neurons in a case--control study ([@B52]). In accordance, miR-133b level is significantly decreased in plasma/serum of PD patients as shown in the current study and a previous report ([@B60]). Interestingly, different from the above *in vitro* model ([@B30]), miR-133b null mice exhibit normal numbers of midbrain dopaminergic neurons during development and aging along with unchanged Pitx3 expression and dopamine release in the striatum ([@B19]). This result indicates that miR-133b *per se* is not sufficient to induce the pathogenesis of PD, or its reduction in PD may merely be a consequence of dopaminergic neuronal loss during disease progression.

In contrast to miR-433, miR-133b, miR-34b, and miR-153, which are stably measurable in plasma, miR-34c and miR-7 are present at very low level in plasma, indicating that these two miRNAs may not be suitable to be biomarkers. On the other hand, our limited sample volume prevents us from detecting these low abundant miRNAs through the use of higher amount of RNA for the original cDNA synthesis. Results from microarray and sequencing analyses show that miR-34c and/or miR-7 are expressed in peripheral blood mononuclear cells (PBMCs) and in serum, although their expression not altered in PD ([@B38]; [@B6]).

Pairwise correlations between miR-433, miR-133b, miR-34b, and miR-153 showed a trend of reduction in the PD group, indicating a differential involvement of these miRNAs in PD pathogenesis and/or pathology. Notably, the strongest correlation is observed between miR-433 and miR-133b, the two miRNAs with significant changes in PD. It appears that aging has no impact on levels of these miRNAs in plasma. However, further studies are needed from populations of wider age range since the age of participants in this study resides in a narrow range. It is surprising that changes in miR-433 and miR-133b expression are not associated with PD severity, although this seems not a sole case ([@B60]; [@B34]). Further studies are needed with larger sample size for each stage.

Potential target genes of miR-433 and miR-133b were involved in various pathways, sharing seven in common. However, no overlap was found in these genes, neither in the biological processes, suggesting that they function likely in a complementary manner. Modeling using data of miR-433 and miR-133b does not generate satisfactory performance for PD prediction. It may attribute to our relative small sample size that limits the cross-validation to build an optimal machine-learning model. On the other hand, it may not be surprising since a single form of biomarker has been considered almost impossible to predict PD and a combination of multiple testing including imaging, biochemical, and genetic is proposed to be required for future success ([@B27]).

Proper normalization is critical for detection of authentic biological differences between samples. Although there is no consensus on the miRNA loading control ([@B31]), many studies have used nucleolar RNA U6 as an internal control to normalize circulating miRNAs ([@B1]; [@B58]; [@B60]), while some studies simply follow a consistent reaction system using no normalization controls as noted earlier ([@B10]; [@B48]). Besides, endogenous miR-16-5p, considered to be similar among individuals in most cases, was occasionally used as an internal control ([@B51]). However, serum or plasma prepared from hemolyzed blood samples may contain miR-16-5p that can be increased by 20- to 30-fold ([@B45]). Exogenous synthesized miRNAs such as *Caenorhabditis elegans* miR-39/54/238 are also used for normalization ([@B41]; [@B5]; [@B54]), which, however, lack the capacity to normalize biological and pathological variations ([@B31]). In general, higher amount of qPCR template can reduce the cycle number and obtain lower Ct value for potentially more stable values, and larger sample size helps the power of analysis ([@B13]). Unfortunately, there is realistic challenges to acquire more volume and more samples such as in the study by [@B42]. In the current study, some Ct values are relatively high in measurements of miR-433 and miR-153. As indicated in Section "Materials and Methods," triplicate repeats are used during each qPCR to help the quality control of reliability. The normalization methods using U6 as an internal control and using no control lead to similar results, suggesting that our reactions are stably performed following a consistent system.

As summarized in **Table [3](#T3){ref-type="table"}**, miRNA biomarkers of PD are investigated in blood, PBMCs, leukocytes, plasma, serum, and CSF. There seems no report in urine and saliva, although cases are found in other diseases such as cancer ([@B43]; [@B59]). Interestingly, the identified differentially expressed miRNAs in PD are varied among studies (**Table [3](#T3){ref-type="table"}**). As mentioned earlier, we selected the six miRNAs based on postmortem evidence in brain and/or regulating α-synuclein expression. Not considering the studies which measure miRNAs individually selected by their respective rationales, results from screenings by arrays or next generation sequencing are surprisingly rarely overlapped ([@B38]; [@B29]; [@B8]; [@B53]; [@B4]; [@B6]; [@B55]; [@B17]; [@B12]; [@B13]). This discrepancy may be attributed to differences in ages, disease stages and subtypes of included patients, threshold of significance in data processing, sample sizes, and type of sources if using different fluids/cells. Of note from the overall results, a decreased level of miR-19b/miR-19b-3p in PD is suggested by four studies, respectively, in PBMCs ([@B38]), serum ([@B4]; [@B7]), and CSF ([@B17]), except one study which shows increased miR-19b-3p expression in CSF ([@B6]). The expression of miR-195 is suggested increased in serum of PD by two studies ([@B12]; [@B7]). The expression of miR-30c is decreased in PD, respectively, in PBMCs ([@B38]) and serum ([@B55]). Decreased levels of miR-133b and miR-433 in plasma of PD as shown in the current study are in line with two previous reports, respectively in serum and CSF ([@B6]; [@B60]). Also, consistent with our results, miR-153 and miR-34b are not reported to be changed in fluids of PD. miR-34c and miR-7, which are not sufficiently detected in our condition, are not suggested to be changed either in PD (**Table [3](#T3){ref-type="table"}**). Further investigations are warranted to clarify how levels of miRNAs change in the fluids of PD in association with PD subtypes and disease progression. Also, the differences may be worth testing in urine and saliva in order to further understand their potentiality to serve as PD biomarkers.

Conclusion
==========

While it is a long haul to eventually identify clinic proven biomarkers, we herein screen and demonstrate that levels of miR-433 and miR-133b, two miRNAs associated with PD pathogenesis, are significantly reduced in plasma of PD patients and not correlated with age, suggesting their specificity and potentiality to serve as biomarkers. Future studies are needed in combination with other testing to upgrade their performance in predicting PD.
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